Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercializ… Read more
Jasper Therapeutics Inc (JSPR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.469x
Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) has a cash flow conversion efficiency ratio of -1.469x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.00 Million) by net assets ($11.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jasper Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Jasper Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jasper Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jasper Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Poznanska Korporacja Budowlana Pekabex SA
WAR:PBX
|
-0.137x |
|
SRV Group plc
HE:SRV1V
|
0.076x |
|
Thai Eastern Group Holdings PCL
BK:TEGH
|
0.105x |
|
Seker Gayrimenkul Yatirim Ortakligi A.S.
IS:SEGYO
|
0.017x |
|
Synergy Green Industries Limited
NSE:SGIL
|
0.056x |
|
Icecure Medical
NASDAQ:ICCM
|
-0.291x |
|
Everyday People Financial Corp.
V:EPF
|
-0.083x |
|
Excellon Resources Inc
PINK:EXNRF
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Jasper Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Jasper Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $61.67 Million | $-62.60 Million | -1.015x | -52.92% |
| 2023-12-31 | $78.44 Million | $-52.07 Million | -0.664x | +47.91% |
| 2022-12-31 | $35.99 Million | $-45.86 Million | -1.274x | -163.02% |
| 2021-12-31 | $69.52 Million | $-33.68 Million | -0.484x | -193.17% |
| 2020-12-31 | $-35.13 Million | $-18.27 Million | 0.520x | +657.27% |
| 2019-12-31 | $21.10 Million | $-1.97 Million | -0.093x | -- |